title: Successful infliximab treatment of steroid and OKT3 refractory acute cellular rejection in two patients after intestinal transplantation.
abstract: Acute rejection resistant to established immunosuppressive rescue protocols remains the most prominent risk factor after intestinal transplantation. In two patients presenting with steroid-resistant severe acute cellular rejection 9 months and 2 years after intestinal transplantation, complete resolution was not achieved despite 5 and 10 days of OKT3 treatment, respectively, and high-dose triple baseline immunosuppression with tacrolimus, rapamycin, and steroids. There was a dissociated course of rejection with persistent moderate to severe rejection in the terminal portion of the graft despite complete recovery from rejection in the proximal parts. Both patients were treated with four subsequent infusions of infliximab (3 mg/kg body weight), a chimeric anti-tumor necrosis factor-alpha antibody. There was an immediate response regarding macroscopic appearance, graft histology, and clinical symptoms. Both patients recovered. In conclusion, infliximab has proven to be an effective rescue therapy in a selected group of patients with steroid and OKT3 refractory severe acute rejection after intestinal transplantation.
authors.affiliation: Department of General and Transplantation Surgery, Charité, Campus Virchow Clinic, Berlin, Germany. andreas.pascher@charite.de.
authors.forename: Andreas
authors.initials: A
authors.lastname: Pascher
authors.forename: Cornelia
authors.initials: C
authors.lastname: Radke
authors.forename: Axel
authors.initials: A
authors.lastname: Dignass
authors.forename: Ralf J
authors.initials: RJ
authors.lastname: Schulz
authors.forename: Winfried
authors.initials: W
authors.lastname: Veltzke-Schlieker
authors.forename: Andreas
authors.initials: A
authors.lastname: Adler
authors.forename: Igor M
authors.initials: IM
authors.lastname: Sauer
authors.forename: Klaus
authors.initials: K
authors.lastname: Platz
authors.forename: Jochen
authors.initials: J
authors.lastname: Klupp
authors.forename: Hans-Dieter
authors.initials: HD
authors.lastname: Volk
authors.forename: Peter
authors.initials: P
authors.lastname: Neuhaus
authors.forename: Andrea R
authors.initials: AR
authors.lastname: Mueller
mesh_terms: D000208:Acute Disease; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069285:Infliximab; D007422:Intestines / Q000637:transplantation*; D008297:Male; D016853:Muromonab-CD3 / Q000627:therapeutic use; D020123:Sirolimus / Q000627:therapeutic use; D013256:Steroids / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D013256:Steroids; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D020123:Sirolimus; D016559:Tacrolimus